Download PDF
Thromb Haemost 1982; 47(02): 109-113
DOI: 10.1055/s-0038-1657140
Original Article
Schattauer GmbH Stuttgart

A Comparison of Pentosan Polysulphate and Heparin II: Effects of Subcutaneous Injection

A-M Fischer
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
R E Merton
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
N A Marsh
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
S Williams
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
P J Gaffney
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
T W Barrowcliffe
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
,
D P Thomas
The National Institute for Biological Standards and Control, Hampstead, London, U.K.
› Author Affiliations
Further Information

Publication History

Received 06 November 1981

Accepted 21 January 1982

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A comparison has been made between the effects of pentosan polysulphate (SP54) and mucosal heparin following subcutaneous injection in man. Unlike heparin, pentosan polysulphate has relatively little effect in vivo as measured by anti-factor Xa clotting assay and none by an anti-Xa amidolytic assay (S-2222). However, pentosan polysulphate is at least as potent as heparin on a weight basis in producing activation of lipoprotein lipase, shortening of the euglobulin clot lysis time and impairing the generation of factor Xa. Our data indicate that pentosan polysulphate has more marked effects in vivo than in vitro, that the action of the drug on clotting is mediated mainly via an At III-independent pathway, and that its effects are not confined to the coagulation system.

Key words

Pentosan polysulphate - Heparin - SP54 - Mechanism in vivo - Subcutaneous injection
 

  • References

  • 1 Joffe S. Drug prevention of postoperative deep vein thrombosis. A comparative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 1976; 111: 37-40
    CrossrefPubMedGoogle Scholar
  • 2 Bergqvist D, Efsing HO, Hallböök T, Lindblad B. Prevention of postoperative thromboembolic complications. A prospective comparison between Dextran 70, Dihydroergotamin-Heparin and a sulphated polysaccharid. Acta Chir Scand 1980; 146: 559-568
    PubMedGoogle Scholar
  • 3 Bergqvist D, Ljungner H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg 1981; 68: 449-451
    CrossrefPubMedGoogle Scholar
  • 4 Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-463
    CrossrefPubMedGoogle Scholar
  • 5 Czapek EE, Kwaan HC, Szczecinski M. The effect of a sulfated polysaccharide on antithrombin III. J Lab Clin Med 1980; 95: 783-790
    PubMedGoogle Scholar
  • 6 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20: 57-68
    CrossrefPubMedGoogle Scholar
  • 7 Halse Th. Aktivierung der Fibrinolyse und Thrombolyse durch Polysaccharidschwefelsäureester (Heparin, Heparinoide). Arzneim Forschung 1962; 12: 574-582
    PubMedGoogle Scholar
  • 8 Thomas DP, Lane DA, Michalski R, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
    PubMedGoogle Scholar
  • 9 Kakkar VV, Lawrence D, Bentley PG, De Haas HA, Ward VP, Scully MF. A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis. Thromb Res 1978; 13: 111-122
    CrossrefPubMedGoogle Scholar
  • 10 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
    CrossrefPubMedGoogle Scholar
  • 11 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
    CrossrefPubMedGoogle Scholar
  • 12 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
    PubMedGoogle Scholar
  • 13 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. I. Mechanism of action. Thromb Haemostas 1982; 47: 104
    PubMedGoogle Scholar
  • 14 Nilsson-Ehle P, Schotz NC. A stable radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 1976; 17: 536
    PubMedGoogle Scholar
  • 15 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
    PubMedGoogle Scholar
  • 16 Marsh NA. Measurement of fibrinolytic capacity by the euglobulin lysis time method – a problem of “units”. Thromb Res 1977; 12: 197-200
    PubMedGoogle Scholar
  • 17 Eika C, Godal HC, Kierulf P. Detection of small amounts of heparin by the thrombin clotting time. Lancet 1972; 2: 376
    PubMedGoogle Scholar
  • 18 Marsh NA, Gaffney PJ. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-247
    PubMedGoogle Scholar
  • 19 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
    CrossrefPubMedGoogle Scholar
  • 20 Rosenberg RD, Oosta GM, Jordan RE, Gardner WT. Mechanism of antithrombin action and the structural basis of heparin’s anticoagulant function. In: Chemistry and Biology of Heparin. Eds. Lundblad RL, Brown WV, Mann KG, Roberts HR. 249-269 Elsevier; North Holland: 1981
    Google Scholar
  • 21 Ofosu F, Blajchmann MA, Hirsh J. The inhibition by heparin of the intrinsic pathway activation of Factor X in the absence of antithrombin III. Thromb Res 1980; 20: 391-403
    CrossrefPubMedGoogle Scholar
  • 22 Walker FJ, Esmon CT. Interactions between heparin and factor Xa. Inhibition of prothrombin activation. Biochim Biophys Acta 1979; 585: 405-415
    CrossrefPubMedGoogle Scholar
  • 23 Markwardt F, Klöcking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6: 370-374
    PubMedGoogle Scholar
  • 24 Bergqvist D, Nilsson IM. A sulphated polysaccharide – the effects in vivo and in vitro on the haemostatic system in healthy volunteers. Thromb Res 1981; 23: 309-315
    CrossrefPubMedGoogle Scholar